Securities & Exchange Commission v. Mannion

28 F. Supp. 3d 1304, 88 Fed. R. Serv. 3d 1596, 2014 WL 2957265, 2014 U.S. Dist. LEXIS 89156
CourtDistrict Court, N.D. Georgia
DecidedJuly 1, 2014
DocketNo. 1:10-cv-3374-WSD
StatusPublished
Cited by3 cases

This text of 28 F. Supp. 3d 1304 (Securities & Exchange Commission v. Mannion) is published on Counsel Stack Legal Research, covering District Court, N.D. Georgia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Securities & Exchange Commission v. Mannion, 28 F. Supp. 3d 1304, 88 Fed. R. Serv. 3d 1596, 2014 WL 2957265, 2014 U.S. Dist. LEXIS 89156 (N.D. Ga. 2014).

Opinion

OPINION AND ORDER

WILLIAM S. DUFFEY, JR., District Judge.

This matter is before the Court on the Commission’s Motion to Dismiss [138] and the Commission’s Motion for Imposition of Remedies [144],

I. BACKGROUND

This is a civil enforcement action brought by the Securities and Exchange Commission (“SEC” or the “Commission”) under the Securities Exchange Act of 1934 (“Exchange Act”) and the Investment Advisers Act of 1940 (“Advisers Act”). On October 19, 2010, the Commission filed its Complaint [1] against Defendants Paul T. Mannion, Jr. (“Mannion”), Andrew S. Reckles (“Reckles”), PEF Advisors Ltd. (“PEF Ltd.”), and PEF Advisors LLC (“PEF LLC”) (collectively, “Defendants”). The Complaint names Palisades Master Fund, L.P. (the “Palisades Fund” or the “Fund”) as Relief Defendant. PEF Ltd. and PEF LLC are alleged to be the investment advisors to Palisades Equity Holdings Ltd. and Palisades Equity Fund, L.P., hedge funds that served as feeder funds for, and otherwise made investments through, the Palisades Fund. Mannion and Reckles are alleged to be the principals and co-owners of PEF Ltd. and PEF LLC.

A. Commission’s Claims and Relevant Procedural Background

In its Complaint, the Commission alleged various fraudulent schemes by Defendants, including that (i) in August, September, and October 2005, Defendants reported monthly “net asset values” (“NAVs”) with inflated values of certain assets held by the Palisades Fund (the ‘Waluation Claim”), and (ii) in July and August 2005, Defendants personally exercised stock warrants, for shares of World Health Alternatives, Inc. (“World Health”), belonging to the Fund (the [1306]*1306“Misappropriation Claim”).1 In Count I of the Complaint, the Commission alleged that Defendants’ actions in connection with these alleged schemes constitute violations of Section 10(b) of the Exchange Act. In Count II, the Commission alleged that Defendants’ actions constitute violations of subsection (1) of Section 206 of the Advisers Act. In Count III, the Commission alleged that Defendants’ actions constitute violations of subsection (2) of Section 206 of the Advisers Act.

On June 28, 2012, and July 30, 2012, the Commission and Defendants filed cross Motions for Summary Judgment [59, 66]. On March 25, 2013, the Court entered its Order [87], 2013 WL 1291621, on the motions (the “Summary Judgment Order”). With respect to the Valuation Claim, the Court found that the record lacked evidence of the amount of the alleged overvaluations stated in the September and October 2005 NAVs. On this basis, the Court concluded that the trier of fact could not determine the amount by which the overvaluations inflated Defendants’ management fees and could not, therefore, determine whether the overvaluations were “material” under Section 206. The Court thus granted Defendants summary judgment on the Valuation Claim asserted under Section 206 based on the September and October 2005 NAVs. The Court further found that, with respect to the August 2005 NAV, the record contained sufficient evidence of “materiality” to allow the Section 206 claims based on the August 2005 NAV to proceed to trial.2

With respect to the Misappropriation Claim, the Court found that the record established Defendants’ liability under Section 206(2), and the Court granted the Commission summary judgment on its Section 206(2) Misappropriation Claim. The Court found that the record showed a genuine dispute as to whether Defendants acted with scienter under Sections 10(b) and 206(1). The Court thus denied summary judgment to both the Commission and Defendants on the Misappropriation Claim asserted under Sections 10(b) and 206(1).

On April 22, 2013, the Commission filed its Motion for Reconsideration [89] of the Court’s Summary Judgment Order. With respect to the Misappropriation Claim, the Commission argued, as it did in its Motion for Summary Judgment, that the record establishes as a matter of law that Defendants acted with scienter in exercising the Palisades Fund’s warrants. In its Order on the Motion for Reconsideration [136] (the “Reconsideration Order”), the Court again found that the facts supporting scienter are in dispute and are required to be decided by the finder of fact at trial.

Following the Court’s Reconsideration Order, the following claims remained to be tried in this matter: (i) that Defendants violated Section 206 of the Advisers Act by overvaluing the August 2005 NAV (the “Section 206 Valuation Claim”); (ii) that Defendants violated Section 10(b) of the Exchange Act by misappropriating the Fund’s World Health warrants (the “Section 10(b) Misappropriation Claim”); and (iii) that Defendants violated Section 206(1) of the Advisers Act by misappropriating the Fund’s World Health warrants (the “Section 206(1) Misappropriation Claim”).

[1307]*1307B. Pending Motions

On March 12, 2014, the Commission filed its Motion to Dismiss seeking to voluntarily dismiss with prejudice, under Rule 41(a) of the Federal Rules of Civil Procedure, all of its claims remaining to be tried, including the Section 206 Valuation Claim, the Section 10(b) Misappropriation Claim, and the Section 206(1) Misappropriation Claim. Defendants consented to the Motion to Dismiss.

On May 19, 2014, the Commission filed its Motion for Imposition of Remedies related to its Section 206(2) Misappropriation Claim, on which the Court previously granted summary judgment in the Commission’s favor. The Commission seeks disgorgement of Defendants’ gains from their exercise of the Palisades Fund’s World Health warrants, a permanent injunction prohibiting Defendants from violating the Advisers Act, and a civil penalty.

II. DISCUSSION

A. Motion to Dismiss

In its Motion to Dismiss, the Commission seeks, under Rule 41(a) of the Federal Rules of Civil Procedure, the voluntary dismissal with prejudice of its Section 206 Valuation Claim, Section 10(b) Misappropriation Claim, and Section 206(1) Misappropriation Claim. Courts uniformly have held that Rule 41(a) does not permit the dismissal of individual claims from a multi-claim action but only authorizes the dismissal of an entire action. See 9 Charles Alan Wright & Arthur R. Miller, Federal Practice and Procedure § 2362, at 413-14 & n. 13 (3d ed. 2008 & Supp.2012) (collecting cases) (“Rule 41(a) is applicable only to the voluntary dismissal of all the claims in an action.”); see also Klay v. United Healthgroup, Inc., 376 F.3d 1092, 1106 (11th Cir.2004) (holding that a district court is “not empowered to dismiss only certain claims under Rule 41”); Exxon Corp. v. Md. Cas. Co., 599 F.2d 659, 662 (5th Cir.1979)3 (holding that Rule 41(a) allows the dismissal of an “action,” not “the separate claims which make up an action”). As many authorities have explained, the proper way for a plaintiff to remove a single claim is to move to amend the complaint under Rule 15. See, e.g., 9 Charles Alan Wright & Arthur R. Miller,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
28 F. Supp. 3d 1304, 88 Fed. R. Serv. 3d 1596, 2014 WL 2957265, 2014 U.S. Dist. LEXIS 89156, Counsel Stack Legal Research, https://law.counselstack.com/opinion/securities-exchange-commission-v-mannion-gand-2014.